Browsing by Subject "Glioma"
Now showing items 1-20 of 29
-
A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.
(PLoS One, 2015)Diffuse intrinsic pontine gliomas (DIPGs) represent a particularly lethal type of pediatric brain cancer with no effective therapeutic options. Our laboratory has previously reported the development of genetically engineered ... -
A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells.
(Neoplasia, 2016-01)Diffuse intrinsic pontine glioma (DIPG) is a rare and incurable brain tumor that arises predominately in children and involves the pons, a structure that along with the midbrain and medulla makes up the brainstem. We have ... -
A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer.
(2011)In many cancer types, infiltration of bone marrow-derived myeloid cells in the tumor microenvironment is often associated with enhanced angiogenesis and tumor progression, resulting in poor prognosis. The polypeptide chemokine ... -
c-Myc is required for maintenance of glioma cancer stem cells.
(PLoS One, 2008)BACKGROUND: Malignant gliomas rank among the most lethal cancers. Gliomas display a striking cellular heterogeneity with a hierarchy of differentiation states. Recent studies support the existence of cancer stem cells in ... -
cAMP stimulates transcription of the beta 2-adrenergic receptor gene in response to short-term agonist exposure.
(Proc Natl Acad Sci U S A, 1989-07)In addition to conveying cellular responses to an effector molecule, receptors are often themselves regulated by their effectors. We have demonstrated that epinephrine modulates both the rate of transcription of the beta ... -
Cancer Stem Cells in Brain Tumors: Identification of Critical Biological Effectors
(2010)Human cancer is a leading cause of morbidity and mortality in the developed world. Contrary to the classical model in which tumors are homogeneously composed of malignant cells, accumulating evidence suggests that subpopulations ... -
Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma.
(BMC Cancer, 2010-05-19)BACKGROUND: Malignant glioma is a rare cancer with poor survival. The influence of diet and antioxidant intake on glioma survival is not well understood. The current study examines the association between antioxidant intake ... -
Differential Angiogenic Capability and Hypoxia Responses in Glioma Stem Cells
(2009)Malignant gliomas are highly lethal cancers characterized by florid angiogenesis. Glioma stem cells (GSCs), enriched through CD133 (Prominin1) selection, are highly tumorigenic and therapy resistance. However, the mechanism ... -
Differential YAP expression in glioma cells induces cell competition and promotes tumorigenesis.
(Journal of cell science, 2019-03-04)Intratumor heterogeneity associates with cancer progression and may account for a substantial portion of therapeutic resistance. Although extensive studies have focused on the origin of the heterogeneity, biological interactions ... -
Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma.
(Acta neuropathologica communications, 2017-05-15) -
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
(Cancer research, 2013-01)Point mutations at Arg132 of the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gliomas and result in a gain of function to produce the "oncometabolite" D-2-hydroxyglutarate (D-2HG). ... -
Driving Brain Tumorigenesis: Generation and Biological Characterization of a Mutant IDH1 Mouse Model
(2014)Despite decades worth of research, glioblastoma remains one of the most lethal cancers. The identification of <italic>IDH1</italic> as a major cancer gene in glioblastoma provides an exceptional opportunity for improving ... -
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.
(The Journal of clinical investigation, 2014-09)Aberrant activation of EGFR in human cancers promotes tumorigenesis through stimulation of AKT signaling. Here, we determined that the discoidina neuropilin-like membrane protein DCBLD2 is upregulated in clinical specimens ... -
Exploring the association between melanoma and glioma risks.
(Ann Epidemiol, 2014-06)PURPOSE: Gliomas are one of the most fatal malignancies, with largely unknown etiology. This study examines a possible connection between glioma and melanoma, which might provide insight into gliomas' etiology. METHODS: ... -
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
(Oncotarget, 2012-07)Mutations in the critical chromatin modifier ATRX and mutations in CIC and FUBP1, which are potent regulators of cell growth, have been discovered in specific subtypes of gliomas, the most common type of primary malignant ... -
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
(Nature, 2022-03)Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal paediatric tumours of the central nervous system1. We have previously shown that the disialoganglioside ... -
Genetic Studies Identify Critical Biomarkers and Refine the Classification of Malignant Gliomas
(2014)Gliomagenesis is driven by a complex network of genetic alterations and while the glioma genome has been a focus of investigation for many years; critical gaps in our knowledge of this disease remain. The identification ... -
Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.
(Nat Genet, 2014-05)Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate ... -
Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
(Current opinion in neurology, 2011-12)Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate isocitrate to α-ketoglutarate (α-KG) and reduce NADP to NADPH. Point mutations of IDH1 and IDH2 have been discovered in gliomas. IDH mutations cause loss of native ... -
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
(Br J Cancer, 2009-12-15)BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. METHODS: A total of 59 patients, including 27 with glioblastoma (GBM) and 32 with grade ...
